Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 531 results for iv

  1. Intravenous infusion of mesenchymal stromal cells in patients with severe recalcitrant psoriasis

    Topic prioritisation

  2. Assessment and monitoring:- What is the incidence of complications during, and as a consequence of, IV fluid therapy?

    monitoring:- What is the incidence of complications during, and as a consequence of, IV fluid therapy? Any explanatory notes(if...

  3. Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making

  4. Intrapartum care for women with existing medical conditions or obstetric complications and their babies (NG121)

    This guideline covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. The guideline also covers women who have had no antenatal care. It aims to improve experiences and outcomes for women and their babies.

  5. Diverticular disease: diagnosis and management (NG147)

    This guideline covers the diagnosis and management of diverticular disease in people aged 18 years and over. It aims to improve diagnosis and care and help people get timely information and advice, including advice about symptoms and when to seek help.

  6. Fluid balance charts:- For children and young people receiving IV fluids, does the use of a standardised national fluid balance chart reduce the rate of complications arising as a result of prescription and/or administration errors?

    Question Fluid balance charts:- For children and young people receiving IV fluids, does the use of a standardised national fluid balance...

  7. Developmental follow-up of children and young people born preterm (NG72)

    This guideline covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It explains the risk of different developmental problems and disorders, and specifies what extra assessments and support children born preterm might need during their growth and development.

  8. Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)

    Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.

  9. Spasticity in under 19s: management (CG145)

    This guideline covers managing spasticity and co-existing motor disorders and their early musculoskeletal complications in children and young people (from birth up to their 19th birthday) with non-progressive brain disorders. It aims to reduce variation in practice and help healthcare professionals to select and use appropriate treatments.

  10. Tegaderm CHG securement dressing for vascular access sites (MIB231)

    NICE has developed a medtech innovation briefing (MIB) on Tegaderm CHG securement dressing for vascular access sites .

  11. Managing anaemia: For adults, children and young people with CKD and anaemia who are on peritoneal dialysis, what amount of intravenous (IV) iron is most clinically and cost effective in managing anaemia and its associated outcomes (including quality of life)?

    with CKD and anaemia who are on peritoneal dialysis, what amount of intravenous (IV) iron is most clinically and cost...

  12. Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia (ES22)

    Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated

  13. Photodynamic therapy for brain tumours (HTG184)

    Evidence-based recommendations on photodynamic therapy for brain tumours. This involves giving the patient a drug that makes the tissue sensitive to light and then activating it with a laser light source to destroy the tumour cells.

  14. Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)

    Evidence-based recommendations on aripiprazole for treating schizophrenia in young people aged 15 to 17.